ZIOPHARM Oncology Inc (ZIOP)

6.44
NASDAQ : Health Care
Prev Close 6.28
Day Low/High 6.06 / 6.50
52 Wk Low/High 4.45 / 11.91
Avg Volume 1.95M
Exchange NASDAQ
Shares Outstanding 131.73M
Market Cap 827.28M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Bullish and Bearish Chart Reversals

What stocks have changed direction in the past week.

ZIOPHARM Reports Third Quarter 2016 Financial Results And Provides Update On Recent Activities

ZIOPHARM Reports Third Quarter 2016 Financial Results And Provides Update On Recent Activities

Company to Host Conference Call on Thursday, November 17, 2016 at 8:00 am ET to Discuss Updated Data from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Brain Cancer Presented at SNO 2016 Annual Meeting

First Week of December 16th Options Trading For ZIOPHARM Oncology (ZIOP)

First Week of December 16th Options Trading For ZIOPHARM Oncology (ZIOP)

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the December 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new December 16th contracts and identified one put and one call contract of particular interest.

Noteworthy Thursday Option Activity: ZIOP, XON, SAM

Noteworthy Thursday Option Activity: ZIOP, XON, SAM

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in ZIOPHARM Oncology Inc , where a total volume of 30,312 contracts has been traded thus far today, a contract volume which is representative of approximately 3.0 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 211.1% of ZIOP's average daily trading volume over the past month, of 1.4 million shares.

Ziopharm Breast Cancer Gene Therapy Tied to 'Higher Than Expected' Toxicity

Ziopharm Breast Cancer Gene Therapy Tied to 'Higher Than Expected' Toxicity

Six of nine breast cancer patients treated with an experimental gene therapy from Ziopharm Oncology ZIOP experienced a potentially dangerous immune system-related toxicity known as cytokine release syndrome.

ZIOPHARM Presents Data Demonstrating Activation Of Anti-Tumor Immune Response Using Ad-RTS-hIL-12 In Patients With Advanced Breast Cancer

ZIOPHARM Presents Data Demonstrating Activation Of Anti-Tumor Immune Response Using Ad-RTS-hIL-12 In Patients With Advanced Breast Cancer

Results Presented at the European Society for Medical Oncology (ESMO) 2016 Congress

5 Stocks Under $10 Poised for Big Breakouts

These under-$10 stocks are within range of triggering breakout trades. Here's how to trade them from here.

First Week of November 18th Options Trading For ZIOPHARM Oncology (ZIOP)

First Week of November 18th Options Trading For ZIOPHARM Oncology (ZIOP)

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the November 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new November 18th contracts and identified one put and one call contract of particular interest.

ZIOP January 2019 Options Begin Trading

ZIOP January 2019 Options Begin Trading

Investors in ZIOPHARM Oncology Inc saw new options become available today, for the January 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 858 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

ZIOP April 2017 Options Begin Trading

ZIOP April 2017 Options Begin Trading

Investors in ZIOPHARM Oncology Inc saw new options begin trading today, for the April 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Ziopharm Oncology (ZIOP) Stock Advances After Q2 Results, Upgrade

Ziopharm Oncology (ZIOP) Stock Advances After Q2 Results, Upgrade

Ziopharm Oncology (ZIOP) reported stronger-than-expected results for the 2016 second quarter following Tuesday's closing bell.

ZIOPHARM Reports Second-Quarter 2016 Financial Results And Provides Update On Recent Activities

ZIOPHARM Reports Second-Quarter 2016 Financial Results And Provides Update On Recent Activities

Company to Host Conference Call at 4:30 PM ET Today

Today's Weak On High Volume Stock: ZIOPHARM Oncology (ZIOP)

Today's Weak On High Volume Stock: ZIOPHARM Oncology (ZIOP)

Trade-Ideas LLC identified ZIOPHARM Oncology (ZIOP) as a weak on high relative volume candidate

Today's Dead Cat Bounce Stock Is ZIOPHARM Oncology (ZIOP)

Today's Dead Cat Bounce Stock Is ZIOPHARM Oncology (ZIOP)

Trade-Ideas LLC identified ZIOPHARM Oncology (ZIOP) as a "dead cat bounce" (down big yesterday but up big today) candidate

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Into Possible Securities Fraud Violations By Certain Officers And Directors Of ZIOPHARM Oncology, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Into Possible Securities Fraud Violations By Certain Officers And Directors Of ZIOPHARM Oncology, Inc.

Levi & Korsinsky announces it has commenced an investigation of ZIOPHARM Oncology, Inc.

Federman & Sherwood Investigates ZIOPHARM Oncology, Inc. For Possible Violations Of Federal Securities Laws

Federman & Sherwood Investigates ZIOPHARM Oncology, Inc. For Possible Violations Of Federal Securities Laws

The law firm of Federman & Sherwood has initiated an investigation into ZIOPHARM Oncology, Inc.